PedAM
Pediatric Disease Annotations & Medicines
| Disease | arteriosclerosis |
| Phenotype | C0027051|heart attack |
| Sentences | 18 |
| PubMedID- 25465417 | Methods: the tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar 2.5 mg daily in 26,449 patients with atherosclerosis, stratified by qualifying disease (mi, pad, or cvd). |
| PubMedID- 24907292 | atherosclerosis, the main cause of heart attack and stroke, is the leading cause of death in most modern countries. |
| PubMedID- 25465416 | Methods: tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) was a multinational, randomized, double-blind, placebo-controlled trial of vorapaxar in stable patients with prior myocardial infarction, peripheral arterial disease, or stroke. |
| PubMedID- 23501976 | Methods and results: the trial to assess the effects of sch 530348 in preventing heart attack and stroke in patients with atherosclerosis (tra2 degrees p-timi 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with stable atherosclerotic vascular disease (myocardial infarction, stroke, or peripheral artery disease). |
| PubMedID- 23248624 | atherosclerosis, the underlying cause of heart attacks and strokes, is a chronic inflammatory disease of the artery wall. |
| PubMedID- 24646491 | atherosclerosis causing heart attack and stroke is the leading cause of death in the modern world. |
| PubMedID- 25483717 | atherosclerosis leads to heart attacks as well as stroke. |
| PubMedID- 20701600 | In old age, these changes are associated with diabetes, hypertension, cancers, cognitive dysfunction, and atherosclerosis leading to heart attacks and strokes (guo et al., 1999; lutz et al., 2008). |
| PubMedID- 25813797 | This article reviews this new class of antiplatelet therapy in detail with an acute focus on the tracer (thrombin receptor antagonist for clinical event reduction in acute coronary syndrome) and tra 2 degrees p-timi 50 (trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50) trials. |
| PubMedID- 26042659 | Conversely, excessive cholesterol causes pathological conditions such as atherosclerosis that can lead to heart attacks. |
| PubMedID- 25722654 | Background: atherosclerosis, the underlying cause of heart attack and strokes, is a progresive dyslipidemic and inflammatory disease where monocyte-derived macrophage cells play a pivotal role. |
| PubMedID- 23776627 | Specifically, people with diabetes suffer from accelerated, severe atherosclerosis, which then leads to heart attack, stroke, and peripheral vascular disease [3], [4]. |
| PubMedID- 26346960 | The trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (tra 2 degrees p-timi 50) investigated atherothrombotic events in patients with stable atherosclerosis. |
| PubMedID- 23493278 | atherosclerosis, the main cause of heart attack and stroke, is the leading cause of death in most modern countries. |
| PubMedID- 24495381 | Luteolin, kaempferol, quercitrin, rutin, myricetin, and vitamin c are powerful antioxidants that inhibit the oxidation of low-density lipoprotein (ldl), a major factor in the promotion of atherosclerosis that can lead to heart attack or stroke. |
| PubMedID- 26318398 | Rationale: a strong risk factor for atherosclerosis- the leading cause of heart attacks and strokes- is the elevation of low-density lipoprotein cholesterol (ldl-c) in blood. |
| PubMedID- 25069568 | atherosclerosis, the major cause of heart attack and stroke, is a chronic inflammatory disease characterized by the formation of atherosclerotic plaque. |
| PubMedID- 23153280 | Reduction of no availability alters vascular homeostasis [50] and is a phenomenon involved in the development of hypertension [50,51], atherosclerosis and thrombosis leading to heart attack and stroke [52-54]. |
Page: 1